Latest Us Market News

Smart Parking Limited reports robust H1 FY25 growth driven by a strategic US acquisition and expanding global footprint, underpinned by proprietary AI technology.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

International Graphite Limited has received encouraging feedback from the U.S. Department of Defense on its proposal for up to US$7.5 million in funding to advance its graphite mine-to-market strategy, potentially securing a vital supply chain from Western Australia to the U.S.

Almonty Industries reports steady tungsten market conditions and completes key financing for its Sangdong Mine, while posting a $34.6 million net loss in Q1 2025. The company advances its US Domestication and plans to restart Los Santos Mine in 2026.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.

Aristocrat Leisure reported a robust first half FY2025 with 9% revenue growth and a 6% rise in normalised NPATA, driven by strategic acquisitions and market share gains. The company returned $533 million to shareholders while positioning for sustained growth across its gaming portfolio.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.